Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2025 18:49 ET | Source: Monteverde & Associates PC

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—TRUE, BRY, EVOK, and FSFG

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for...
November 13, 2025 07:00 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update

Entered into an Agreement to be acquired by QOL Medical Net product sales for the third quarter of 2025 reached $4.3 million; up 61% year-over-year Gimoti patent life for Gimoti extended...
November 04, 2025 18:00 ET | Source: Monteverde & Associates PC

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Evoke Pharma, Inc. (NASDAQ: EVOK)

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for...
August 21, 2025 07:00 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book

SOLANA BEACH, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
August 14, 2025 07:00 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update

SOLANA BEACH, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an...
April 28, 2025 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025

SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an...
March 13, 2025 16:02 ET | Source: Evoke Pharma, Inc.

Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient...
March 06, 2025 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025

SOLANA BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an...
February 24, 2025 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors

SOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
December 19, 2024 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends

FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical...